Celltrion Financial Statements From 2010 to 2024
| 068760 Stock | KRW 59,800 1,300 2.13% |
Check Celltrion Pharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celltrion Pharm's main balance sheet or income statement drivers, such as , as well as many indicators such as . Celltrion financial statements analysis is a perfect complement when working with Celltrion Pharm Valuation or Volatility modules.
Celltrion |
Celltrion Pharm Company Current Valuation Analysis
Celltrion Pharm's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Celltrion Pharm Current Valuation | 5.87 T |
Most of Celltrion Pharm's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Celltrion Pharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Celltrion Pharm has a Current Valuation of 5.87 T. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all Republic of Korea stocks is notably lower than that of the firm.
Celltrion Pharm Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Celltrion Pharm's current stock value. Our valuation model uses many indicators to compare Celltrion Pharm value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Celltrion Pharm competition to find correlations between indicators driving Celltrion Pharm's intrinsic value. More Info.Celltrion Pharm is rated fourth in return on equity category among its peers. It also is rated fourth in return on asset category among its peers reporting about 0.38 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Celltrion Pharm is roughly 2.61 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Celltrion Pharm by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Celltrion Pharm's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Celltrion Pharm Financial Statements
Celltrion Pharm stakeholders use historical fundamental indicators, such as Celltrion Pharm's revenue or net income, to determine how well the company is positioned to perform in the future. Although Celltrion Pharm investors may analyze each financial statement separately, they are all interrelated. For example, changes in Celltrion Pharm's assets and liabilities are reflected in the revenues and expenses on Celltrion Pharm's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Celltrion Pharm. Please read more on our technical analysis and fundamental analysis pages.
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju, South Korea. Celltrionph is traded on Korean Securities Dealers Automated Quotations in South Korea.
Pair Trading with Celltrion Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Celltrion Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Celltrion Pharm will appreciate offsetting losses from the drop in the long position's value.Moving together with Celltrion Stock
Moving against Celltrion Stock
| 0.84 | 122870 | YG Entertainment | PairCorr |
| 0.8 | 041510 | SM Entertainment | PairCorr |
| 0.75 | 003535 | Hanwha InvestmentSecuri | PairCorr |
| 0.73 | 012330 | Hyundai Mobis | PairCorr |
| 0.69 | 032640 | LG Uplus | PairCorr |
The ability to find closely correlated positions to Celltrion Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Celltrion Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Celltrion Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Celltrion Pharm to buy it.
The correlation of Celltrion Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Celltrion Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Celltrion Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Celltrion Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Celltrion Stock
Celltrion Pharm financial ratios help investors to determine whether Celltrion Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Celltrion with respect to the benefits of owning Celltrion Pharm security.